IGC Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q3 2025Q2 2025
Revenue
328.0K
+23.8%
265.0K
-16.4%
317.0K
+66.0%
191.0K
-41.8%
328.0K
Cost of Revenue
267.0K
+23.0%
217.0K
-17.2%
262.0K
+184.8%
92.0K
-47.1%
174.0K
Gross Profit
61.0K
+27.1%
48.0K
-12.7%
55.0K
-44.4%
99.0K
-35.7%
154.0K
Operating Expenses
2.0M
-29.7%
2.8M
+12.7%
2.5M
-16.2%
3.0M
+45.6%
2.1M
R&D
1.0M
-27.1%
1.4M
+9.3%
1.3M
-19.9%
1.6M
+86.6%
851.0K
SG&A
979.0K
-32.1%
1.4M
+16.2%
1.2M
-12.0%
1.4M
+16.7%
1.2M
Operating Income
-1931000
+30.6%
-2784000
-13.3%
-2458000
+15.2%
-2899000
-52.2%
-1905000
EBITDA
-1873000
+31.3%
-2728000
-13.7%
-2400000
+13.7%
-2780000
-57.6%
-1764000
Net Income
-2046000
+30.3%
-2936000
-22.2%
-2402000
-31.9%
-1821000
-13.9%
-1599000
EPS (Basic)
$-0.02
+33.3%
$-0.03
-50.0%
$-0.02
+0.0%
$-0.02
+0.0%
$-0.02
EPS (Diluted)
$-0.02
+33.3%
$-0.03
-50.0%
$-0.02
+0.0%
$-0.02
+0.0%
$-0.02
Shares (Diluted)
109.5M
+9.1%
100.3M
+2.2%
98.2M
+8.5%
90.5M
+8.9%
83.0M
IGC Pharma (IGC) — Financials